Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term CELL LUNG-CANCER. Found 16 abstracts

Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets. 2009 Mar;13(3):339-62.   PMCID: PMC2670612
Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris H, Schellens JH. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 2009 Mar;47(3):195-206.   PMCID: not NIH funded
Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. Journal of Clinical Oncology. 2008 Mar;26(9):1465-71.
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A radiation therapy oncology group analysis. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):353-60.
Chetty IJ, Curran B, Cygler JE, DeMarco JJ, Ezzell G, Faddegon BA, Kawrakow I, Keall PJ, Liu H, Ma CM, Rogers DW, Seuntjens J, Sheikh-Bagheri D, Siebers JV. Report of the AAPM Task Group No. 105: Issues associated with clinical implementation of Monte Carlo-based photon and electron external beam treatment planning. Medical Physics. 2007 Dec;34(12):4818-53.
de Caceres, Cairns P. Methylated DNA sequences for early cancer detection, molecular classification and chemotherapy response prediction. Clinical & Translational Oncology. 2007 Jul;9(7):429-37.
Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. Phase II study of erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group study. Journal of Clinical Oncology. 2007 Jun;25(17):2406-13.
Hecht JR, Patnaik A, Berlin J, Venook A, Malik L, Tchekmedyian S, Navale L, Amado RG, Meropol NJ. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007 Sep;110(5):980-8.
Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets. 2007 Dec;11(12):1587-609.
Lutz ST, Chow EL, Hartsell WF, Konski AA. A review of hypofractionated palliative radiotherapy. Cancer. 2007 Apr;109(8):1462-70.
Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007 Apr;109(7):1323-30.
Bruner DW, Movsas B, Konski A, Roach M, Bondy M, Scarintino C, Scott C, Curran W. Outcomes research in cancer clinical trial cooperative groups: The RTOG model. Quality of Life Research. 2004 Aug;13(6):1025-41.
Konski A, Watkins-Bruner D. The RTOG Outcomes Model: economic end points and measures. Expert Opinion on Pharmacotherapy. 2004 Mar;5(3):513-9.
Look KY, Bookman MA, Schol J, Herzog TJ, Rocereto T, Vinters J. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecologic Oncology. 2004 Jan;92(1):93-100.
Schnoll RA, Rothman RL, Lerman C, Miller SM, Newman H, Movsas B, Sherman E, Ridge JA, Unger M, Langer C, Goldberg M, Scott W, Cheng J. Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck. 2004 Mar;26(3):278-86.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term CELL LUNG-CANCER

CELL LUNG-CANCER KeyWords Plus: PROSTATE-CANCER ovarian cancer EPIDERMAL-GROWTH-FACTOR RADIOTHERAPY SURVIVAL CARCINOMA EXPRESSION PROGNOSTIC-FACTORS economic analysis cetuximab CETUXIMAB THERAPY CISPLATIN CLINICAL-TRIALS BREAST-CANCER GROWTH-FACTOR RECEPTOR ADJUSTED SURVIVAL ANALYSIS OPEN-LABEL clinical trials outcomes research SMOKERS COSTS selection bias RANDOMIZED PHASE-III IRESSA PLATINUM PROLONGED ORAL ETOPOSIDE RADIATION-THERAPY-COMMITTEE PATIENTS RECEIVING CHEMOTHERAPY CONTINUED TOBACCO USE combination therapy COMBINATION PLUS IRINOTECAN RECEPTOR TYROSINE KINASE epidermal growth factor receptor panitumumab-human monoclonal antibody-colorectal cancer INTRAVENOUS TOPOTECAN PACLITAXEL PLUS CARBOPLATIN ADVANCED PELVIC INTENSITY-MODULATED RADIOTHERAPY ABC transporter GENE MEK FUNCTIONAL ASSESSMENT PHASE-SPACE MODEL LEUKEMIA GROUP-B QUALITY-OF-LIFE network gefitinib quality of life prognostic hypofractionation BIOAVAILABILITY SENSITIVITY ONCOLOGY GROUP RTOG locoregional control SINGLE FRACTION RADIATION-THERAPY LEUCOVORIN BLADDER-CANCER PHASE-II TRIAL decliners cancer EGFR B-Raf C-RAF CPG GENE COPY NUMBER PROMOTER HYPERMETHYLATION MONOCLONAL-ANTIBODY DRUG-RESISTANCE MEDICAL LINEAR ACCELERATORS ANTITUMOR-ACTIVITY transduction CARBOPLATIN DISEASE chemotherapy response GROWTH-FACTOR-RECEPTOR PAINFUL BONE METASTASES paclitaxel proteomics MALIGNANCIES PHASE-III PAPILLARY THYROID-CARCINOMA signal cancer recruitment INVASIVE BLADDER-CANCER IMMUNOHISTOCHEMICAL EXPRESSION ZD1839 Ras MONOCLONAL-ANTIBODIES ACUTE CHEMOTHERAPY feasibility trial DRUG EPIDEMIC NECK-CANCER FACTOR RECEPTOR INHIBITORS MALIGNANT GLIOMA MULTIPLE FRACTIONS TOPOISOMERASE-I DOXORUBICIN HIGH-ENERGY PHOTON GSTP1 HYPERMETHYLATION radiotherapy EGF RECEPTOR 8 GY early cancer diagnosis RECEPTOR CPG ISLAND TOXICITY CRITERIA symptom control C-RAF-1 c-RAF-1 INTERGROUP TRIAL carboplatin epidermal growth factor receptor PROTEIN MICROARRAYS EORTC QLQ-C30 antibody antisense inhibitor PARTICIPATION INTERVENTION systems biology PROTOCOL MYELOID-LEUKEMIA EGFR MUTATIONS protein array smoking VALIDITY NETWORK X-RAY-BEAMS ANTISENSE OLIGONUCLEOTIDE head and neck cancer epidermal growth factor methylation biomarkers PREDICTORS ACUTE MYELOID-LEUKEMIA TUMOR PHASE-III TRIAL TYROSINE KINASE INHIBITORS phase II ADULT PATIENTS COST-EFFECTIVENESS ANALYSIS METHYLTRANSFERASES TOXICITY GYNECOLOGIC-ONCOLOGY-GROUP METASTATIC COLORECTAL-CANCER RENAL-CANCER DNA hypermethylation
Last updated on Friday, December 06, 2019